Diagnos (TSE:ADK) has released an update.
Diagnos Inc., a Canadian AI tech firm specializing in early health issue detection, announced the granting of 1,550,000 stock options to its directors and officers. These options will vest over two years, starting from their grant date on October 3, 2024, and have an exercise price of $0.37 per common share with an expiry on October 3, 2029.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.
